Atlas Trials

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Clinical trial NCT02624700 · TERMINATED

Trial details

NCT number
NCT02624700
Sponsor
Virginia Commonwealth University
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Start date
2016-01-28
Primary completion
2019-07-10
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.